Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages 273-288

  Melmed, Shlomo ^a   Casanueva, Felipe F ^b   Hoffman, Andrew R ^c   Kleinberg, David L ^d   Montori, Victor M ^e   Schlechte, Janet A ^f   Wass, John A H ^g  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC ROCHESTER   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BROMOCRIPTINE; BUTYROPHENONE; CABERGOLINE; CISPLATIN; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; ETOPOSIDE; LEVOTHYROXINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; ORAL CONTRACEPTIVE AGENT; PHENOTHIAZINE; PROCARBAZINE; PROGESTERONE; PROLACTIN; QUINAGOLIDE; RISPERIDONE; TEMOZOLOMIDE; VERAPAMIL; VINCRISTINE; ZIPRASIDONE;

BLOOD ANALYSIS; BREAST FEEDING; CONSENSUS DEVELOPMENT; DIAGNOSTIC PROCEDURE; DRUG INDUCED HYPERPROLACTINEMIA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; E-MAIL; EVIDENCE BASED MEDICINE; EXERCISE; GRADING OF RECOMMENDATION, ASSESSMENT, DEVELOPMENT, AND EVALUATION SYSTEM; HEALTH CARE QUALITY; HISTORY; HUMAN; HYPERPROLACTINEMIA; INFERTILITY; MEDICAL EXPERT; MEDICAL SOCIETY; MICROADENOMA; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REVIEW; SCORING SYSTEM; SLEEP; STRESS; TREATMENT INDICATION; TRICUSPID VALVE REGURGITATION;

ADULT; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERPROLACTINEMIA; PITUITARY NEOPLASMS; PREGNANCY; PROLACTINOMA;

EID: 79951685894     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1692     Document Type: Review

References (137)

1. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT, Varonen H, Vist GE, Williams Jr JW, Zaza S 2004 Grading quality of evidence and strength of recommendations. BMJ 328:1490
2. Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM 2008 A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 93:666-673 (Pubitemid 351398536)
3. Melmed S 2003 Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112:1603-1618 (Pubitemid 38063716)
4. Frantz AG, Kleinberg DL 1970 Prolactin: evidence that it is separate from growth hormone in human blood. Science 170:745-747
5. Hwang P, Guyda H, Friesen H 1971 A radioimmunoassay for human prolactin. Proc Natl Acad Sci USA 68:1902-1906
6. Kleinberg DL, Noel GL, Frantz AG 1977 Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 296:589-600 (Pubitemid 8055022)
7. Gillam MP, Molitch ME, Lombardi G, Colao A 2006 Advances in the treatment of prolactinomas. Endocr Rev 27:485-534 (Pubitemid 44213229)
8. Klibanski A 2010 Clinical practice. Prolactinomas. N Engl J Med 362:1219-1226
9. Schlechte JA 2003 Clinical practice. Prolactinoma. N Engl J Med 349:2035-2041
10. Schlechte J, el-Khoury G, Kathol M, Walkner L 1987 Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64:1021-1026
11. Buurman H, Saeger W 2006 Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol 154:753-758 (Pubitemid 43810863)
12. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A 2006 High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769-4775 (Pubitemid 44917305)
13. Fernandez A, Karavitaki N, Wass JA 2010 Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377-382
14. Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, Dekkers OM 2009 Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94:2729-2734
15. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A 2006 Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265-273 (Pubitemid 44079693)
16. Mancini T, Casanueva FF, Giustina A 2008 Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37:67-99, viii
17. Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro Jr R, Barros AI, Faria M, Nascimento GC, Lima JG, Nóbrega LH, Cruz TP, Mota A, Ramos A, Violante A, Lamounier Filho A, Gadelha MR, Czepielewski MA, Glezer A, Bronstein MD 2008 Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest 31:436-444 (Pubitemid 352005743)
18. Kearns AE, Goff DC, Hayden DL, Daniels GH 2000 Risperidone-associated hyperprolactinemia. Endocr Pract 6:425-429
19. Hattori N 2003 Macroprolactinemia: a new cause of hyperprolactinemia. J Pharmacol Sci 92:171-177 (Pubitemid 36992303)
20. Chahal J, Schlechte J 2008 Hyperprolactinemia. Pituitary 11:141-146
21. Glezer A, Soares CR, Vieira JG, Giannella-Neto D, Ribela MT, Goffin V, Bronstein MD 2006 Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab 91:1048-1055 (Pubitemid 43357779)
22. Donadio F, Barbieri A, Angioni R, Mantovani G, Beck-Peccoz P, Spada A, Lania AG 2007 Patients with macroprolactinaemia: clinical and radiological features. Eur J Clin Invest 37:552-557 (Pubitemid 46920193)
23. McKenna TJ 2009 Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxf) 71:466-469
24. Gibney J, Smith TP, McKenna TJ 2005 The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 90:3927-3932 (Pubitemid 41058153)
25. Barkan AL, Chandler WF 1998 Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report. Neurosurgery 42:913-915; discussion 915-916
26. Petakov MS, Damjanoviæ SS, Nikoliæ-Duroviæ MM, Dragojloviæ ZL, Obradoviæ S, Gligoroviæ MS, Simiæ MZ, Popoviæ VP 1998 Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 21:184-188 (Pubitemid 28223066)
27. Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ 2002 Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 87:5410-5415 (Pubitemid 36034335)
28. Melmed S, Kleinberg D 2008 Anterior pituitary. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders Elsevier; 185-261
29. Hou SH, Grossman S, Molitch ME 1985 Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 6:245-249 (Pubitemid 16257626)
30. Lim VS, Kathpalia SC, Frohman LA 1979 Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab 48:101-107 (Pubitemid 9101617)
31. Sievertsen GD, Lim VS, Nakawatase C, Frohman LA 1980 Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab 50:846-852 (Pubitemid 10016437)
32. Honbo KS, van Herle AJ, Kellett KA 1978 Serum prolactin levels in untreated primary hypothyroidism. Am J Med 64:782-787 (Pubitemid 8328125)
33. Molitch ME 1992 Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 21:877-901 (Pubitemid 23005089)
34. Ahmed M, Banna M, Sakati N, Woodhouse N 1989 Pituitary gland enlargement in primary hypothyroidism: a report of 5 cases with follow-up data. Horm Res 32:188-192 (Pubitemid 20123413)
35. Keye WR, Yuen BH, Knopf RF, Jaffe RB 1976 Amenorrhea, hyperprolactinemia and pituitary enlargement secondary to primary hypothyroidism. Successful treatment with thyroid replacement. Obstet Gynecol 48:697-702
36. Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JA 2006 Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified nonfunctioning pituitary macroadenoma. Clin Endocrinol (Oxf) 65:524-529 (Pubitemid 44414278)
37. Sluijmer AV, Lappöhn RE 1992 Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 58:72-77
38. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A 1989 The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412-418 (Pubitemid 19052886)
39. Bonert VS, Melmed S 2006 Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab 2:408-412 (Pubitemid 44050110)
40. Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA 2009 Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 19:373-382
41. Pollock A, McLaren EH 1998 Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol (Oxf) 49:513-516 (Pubitemid 28475345)
42. Spitzer M, Sajjad R, Benjamin F 1998 Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol 91:693-695 (Pubitemid 28208857)
43. Cutler AJ 2003 Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 28(Suppl 1):69-82 (Pubitemid 36015662)
44. Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ 2003 What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 28(Suppl 2):109-123
45. Smith S, Wheeler MJ, Murray R, O'Keane V 2002 The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 22:109-114
46. Ataya K, Mercado A, Kartaginer J, Abbasi A, Moghissi KS 1988 Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 50:876-881 (Pubitemid 19017956)
47. Misra M, Papakostas GI, Klibanski A 2004 Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 65:1607-1618
48. Meltzer HY, Fang VS 1976 Serum prolactin levels in schizophrenia-effect of antipsychotic drugs: a preliminary report. In: Sachar EJ, ed. Hormones, behavior, and psychopathology. New York: Raven Press
49. Johnsen E, Kroken RA, Abaza M, Olberg H, Jørgensen HA 2008 Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol 28:686-690
50. Molitch ME 2005 Medication-induced hyperprolactinemia. Mayo Clin Proc 80:1050-1057 (Pubitemid 41099391)
51. Bart G, Borg L, Schluger JH, Green M, Ho A, Kreek MJ 2003 Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther 306:581-587 (Pubitemid 36886157)
52. Tolis G, Hickey J, Guyda H 1975 Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab 41:797-800
53. Zis AP, Haskett RF, Albala AA, Carroll BJ 1984 Morphine inhibits cortisol and stimulates prolactin secretion in man. Psychoneuroendocrinology 9:423-427 (Pubitemid 15181545)
54. Mendelson JH, Mello NK, Teoh SK, Ellingboe J, Cochin J 1989 Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab 69:1256-1260 (Pubitemid 20010056)
55. Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB 1985 Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 65:506-510 (Pubitemid 15099148)
56. Kinon BJ, Gilmore JA, Liu H, Halbreich UM 2003 Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 28(Suppl 2):55-68 (Pubitemid 36332229)
57. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA 2004 Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65:57-61
58. Lu ML, Shen WW, Chen CH 2008 Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 32:1978-1981
59. Saitis M, Papazisis G, Katsigiannopoulos K, Kouvelas D 2008 Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia. Psychiatry Clin Neurosci 62:624
60. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM 2006 Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91:1995-2010 (Pubitemid 43854972)
61. Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E 2004 Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 65:187-190
62. Cohen LG, Biederman J 2001 Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 11:435-440 (Pubitemid 34117293)
63. Smith S 1992 Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med 37:737-740
64. Tollin SR 2000 Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 23:765-770 (Pubitemid 32041058)
65. Konopka P, Raymond JP, Merceron RE, Seneze J 1983 Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 146:935-938 (Pubitemid 13037268)
66. Glasziou P, Chalmers I, Rawlins M, McCulloch P 2007 When are randomised trials unnecessary? Picking signal from noise. BMJ 334:349-351 (Pubitemid 46328045)
67. Antunes JL, Housepian EM, Frantz AG, Holub DA, Hui RM, Carmel PW, Quest DO 1977 Prolactin-secreting pituitary tumors. Ann Neurol 2:148-153
68. Kleinberg DL, Frantz AG 1971 Human prolactin: measurement in plasma by in vitro bioassay. J Clin Invest 50:1557-1568
69. Klibanski A, Greenspan SL 1986 Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315:542-546 (Pubitemid 16014768)
70. Melmed S, Braunstein GD, Chang RJ, Becker DP 1986 Pituitary tumors secreting growth hormone and prolactin. Ann Intern Med 105:238-253 (Pubitemid 16039304)
71. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A 2000 Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85:3053-3057
72. Berinder K, Stackenäs I, Akre O, Hirschberg AL, Hulting AL 2005 Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol (Oxf) 63:450-455 (Pubitemid 41442340)
73. Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, L'Hermite M, Ciccarelli E 1992 Dosedependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. Clin Endocrinol (Oxf) 37:534-541
74. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G 2000 Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247-2252 (Pubitemid 32269250)
75. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A 1999 Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518-2522
76. De Rosa M, Zarrilli S, Vitale G, Di Somma C, Orio F, Tauchmanova' L, Lombardi G, Colao A 2004 Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 89:621-625 (Pubitemid 38269868)
77. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G 2004 Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89:1704-1711 (Pubitemid 38507923)
78. De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A, Lombardi G, Colao A 2006 The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf) 64:307-313
79. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A 2001 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256-5261 (Pubitemid 33070245)
80. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K 2008 Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93:4721-4727
81. Pascal-Vigneron V, Weryha G, Bosc M, Leclere J 1995 [Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study]. Presse Med 24:753-757
82. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331:904-909 (Pubitemid 24299871)
83. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698-705
84. Corenblum B, Donovan L 1993 The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 59:671-673 (Pubitemid 23086332)
85. Testa G, Vegetti W, Motta T, Alagna F, Bianchedi D, Carlucci C, Bianchi M, Parazzini F, Crosignani PG 1998 Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58:69-73 (Pubitemid 28449359)
86. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS 2005 Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63:26-31 (Pubitemid 40966398)
87. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G 2003 Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023-2033 (Pubitemid 37448925)
88. Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM 2010 Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95:43-51
89. Kharlip J, Salvatori R, Yenokyan G, Wand GS 2009 Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94:2428-2436
90. Klibanski A 2009 Dopamine agonist therapy in prolactinomas: when can treatment be discontinued? J Clin Endocrinol Metab 94:2247-2249
91. Molitch ME 2003 Dopamine resistance of prolactinomas. Pituitary 6:19-27 (Pubitemid 37455641)
92. Kukstas LA, Domec C, Bascles L, Bonnet J, Verrier D, Israel JM, Vincent JD 1991 Different expression of the two dopaminergic D2 receptors, D2415 and D2444, in two types of lactotroph each characterised by their response to dopamine, and modification of expression by sex steroids. Endocrinology 129:1101-1103
93. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A 1989 Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500-509 (Pubitemid 19221218)
94. Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Becker W 1995 Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report. J Neurosurg 82:886-890
95. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D 2009 Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160:747-752
96. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E 2007 Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38 (Pubitemid 46041751)
97. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46 (Pubitemid 46041752)
98. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E 2008 Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 62:1864-1869
99. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA 2009 Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 70:104-108
100. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM 2008 Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93:3348-3356
101. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A 2008 Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1-5 (Pubitemid 351969123)
102. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O 2009 Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12:153-157
103. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL 2008 Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159:R11-14
104. Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S 2008 Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 15:905-915
105. Jaffe CA, Barkan AL 1992 Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 21:713-735
106. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G 1997 Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876-883 (Pubitemid 27106605)
107. Freda PU, Andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs TP, Wardlaw SL 2000 Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab 85:8-13 (Pubitemid 32268782)
108. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M 2002 Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 87:3180-3186 (Pubitemid 34816362)
109. Serri O, Rasio E, Beauregard H, Hardy J, Somma M 1983 Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 309:280-283 (Pubitemid 13074919)
110. Brada M, Jankowska P 2008 Radiotherapy for pituitary adenomas. Endocrinol Metab Clin North Am 37:263-275, xi
111. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB 2005 Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90:3089-3099 (Pubitemid 40686369)
112. Kars M, Roelfsema F, Romijn JA, Pereira AM 2006 Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol 155:523-534 (Pubitemid 44636871)
113. Popadiæ A, Witzmann A, Buchfelder M, Eiter H, Komminoth P 1999 Malignant prolactinoma: case report and review of the literature. Surg Neurol 51:47-54; discussion 54-55
114. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP 2006 Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7:518-520 (Pubitemid 43796152)
115. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ 2009 Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71:226-233
116. Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M 2009 Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161:631-637
117. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38:185-189 (Pubitemid 44880216)
118. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane Jr JA, Vance ML, Thorner MO, Laws Jr ER, Lopes MB 28 July 2010 Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95:E280-E290
119. Bigazzi M, Ronga R, Lancranjan I, Ferraro S, Branconi F, Buzzoni P, Martorana G, Scarselli GF, Del Pozo E 1979 A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. J Clin Endocrinol Metab 48:9-12 (Pubitemid 9101602)
120. Molitch ME 2006 Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 35:99-116, vi
121. Raymond JP, Goldstein E, Konopka P, Leleu MF, Merceron RE, Loria Y 1985 Follow-up of children born of bromocriptine-treated mothers. Horm Res 22:239-246 (Pubitemid 15239636)
122. Christin-Maître S, Delemer B, Touraine P, Young J 2007 Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris) 68:106-112 (Pubitemid 47241115)
123. Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL 2008 Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 68:66-71 (Pubitemid 350243483)
124. Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T 2010 Individualized highdose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95:2672-2679
125. Robert E, Musatti L, Piscitelli G, Ferrari CI 1996 Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10:333-337 (Pubitemid 26310263)
126. Bronstein MD 2005 Prolactinomas and pregnancy. Pituitary 8:31-38 (Pubitemid 44680083)
127. Webster J 1996 A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14:228-238 (Pubitemid 26128812)
128. Rigg LA, Lein A, Yen SS 1977 Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 129:454-456 (Pubitemid 8211790)
129. Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ 1988 Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med 85:217-220
130. Divers Jr WA, Yen SS 1983 Prolactin-producing microadenomas in pregnancy. Obstet Gynecol 62:425-429 (Pubitemid 14231071)
131. Crosignani PG, Mattei AM, Severini V, Cavioni V, Maggioni P, Testa G 1992 Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol 44:175-180
132. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J 1996 Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 45:299-303 (Pubitemid 26306698)
133. Kupersmith MJ, Rosenberg C, Kleinberg D 1994 Visual loss in pregnant women with pituitary adenomas. Ann Intern Med 121:473-477
134. Molitch ME 1999 Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 28:143-169, vii
135. Johnston DG, Prescott RW, Kendall-Taylor P, Hall K, Crombie AL, Hall R, McGregor A, Watson MJ, Cook DB 1983 Hyperprolactinemia. Long-term effects of bromocriptine. Am J Med 75:868-874 (Pubitemid 13023296)
136. Scheithauer BW, Sano T, Kovacs KT, Young Jr WF, Ryan N, Randall RV 1990 The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65:461-474 (Pubitemid 20154331)
137. Heaney AP, Fernando M, Melmed S 2002 Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest 109:277-283 (Pubitemid 34083748)